“Covid-19 Vaccine” Science-Research, December 2021, Week 4 — summary from ClinicalTrials.gov, Europe PMC and DOAJ

ClinicalTrials.gov — summary generated by Brevi Assistant

This research is to identify SARS-CoV-2 S protein specific CD8 T cells in the blood of COVID-19 vaccinated individuals. As both vaccinations are mRNA based encoding S healthy protein of SARS-CoV-2 and call for 2 doses, the CD8 T cell response is expected to be equivalent. By analyzing the frequency, differentiation, and expansion of these SARS-CoV-2 S protein specific CD8 T cells, we want to shed light right into the CD8 T cell response to COVID-19 vaccine and its modification with age. The SARS-CoV-2 episode has triggered millions of deaths around the world. It has been reported for other Covid-19 vaccines that a longer dose period of approximately 12 weeks in between first and second doses might additionally increase vaccine immunogenicity and protection. This trial will check the very same dosage of the authorised vaccine as used in the critical Phase 3 test but just with a varying time window in between the 2 doses. This is a stage I, open-label medical study to assess the ability of UB-612 vaccine to boost resistance of subjects who previously obtained 2 doses of AstraZeneca COVID-19 vaccine with an 8–16 week interval between first and second dosages. The previous COVID-19 vaccine series will have been finished at least 6 months before research study enrollment. Subjects will be enrolled to get one dosage of 100 μg UB-612 vaccine at Day 1. This research is a randomized, open, control phase medical trial of inactivated COVID-19 vaccine. In this research study,96 subjects that finished key immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co., Ltd. Will obtain one dose of booster immunization with suspended COVID-19 vaccine produced by Sinovac Research & Development Co., Ltd. 192 topics who completed main booster shot with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co., Ltd. Will be arbitrarily divided right into 2 groups in a 1:1 ratio and receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co., Ltd. And Beijing institute of Biological Products Co., Ltd, specifically. Sickle cell condition is a genetic problem brought on by a single base alternative of valine for a glutamine at the sixth amino acid of the genetics encoding for the hemoglobin β chain. Patients with Hgb SS disease and various other sickle hemoglobinopathies deal with a range of clinical difficulties connected to this uncommon hemoglobin. Data recommend that basic immune function in SCD patients might be damaged, and therefore responses to vaccine might be suboptimal. This is a randomized, phase II trial which will be conducted among volunteers aged 18 years and over in Karachi, Lahore and Islamabad, Pakistan. The detectives will be assessing the safety and security and reactogenicity of heterologous and homologous COVID-19 vaccines and identify the immune responses utilizing quasi neutralizing antibodies against SARS-CoV-2 in COVID seronegative participants immunized with heterologous and homologous COVID-19 vaccinations routines.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

• https://clinicaltrials.gov/ct2/show/NCT04852289 — A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans.
• https://clinicaltrials.gov/ct2/show/NCT05148871 — A Community-based Phase 2 3b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine).
• https://clinicaltrials.gov/ct2/show/NCT05167253 — A Phase I, Open-label Study to Evaluate the Ability of UB-612 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
• https://clinicaltrials.gov/ct2/show/NCT05165732 — A Randomized, Open, Control Phase ⅠV Clinical Trial, to Evaluate One Booster Immunization of Inactivated COVID-19 Vaccine (CoronaVac) or Original Vaccine in Adults Aged 18–45 Years Old Previously Vaccinated With Inactivated COVID-19 Vaccine From Difference Manufactures.
• https://clinicaltrials.gov/ct2/show/NCT05139992 — COVID-19 Vaccine Response in People Living With Sickle Cell Disease.
• https://clinicaltrials.gov/ct2/show/NCT05162482 — Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial.

Europe PMC — summary generated by Brevi Assistant

INTRO: As the protection from the COVID-19 injections lessens gradually, wellness authorities are presently considering how to keep resistance by methods of vaccine booster doses. In a recent study, we checked out COVID-19 booster vaccine determination among Danes, a population with a high approval of the initial round of COVID-19 vaccination. 3 coronavirus condition 2019 vaccinations have been authorized for usage in the United States; particularly, the Pfizer-BioNTech, Moderna, and Johnson & Johnson-Janssen COVID-19 injections were approved emergency use consent by the U. S. Food and Drug Administration in late 2020 and early 2021. Here, we discuss the existing scientific data sustaining COVID-19 vaccine security and efficacy in people that are intending to conceive or that are breast feeding or expectant and highlight the relevance of COVID-19 vaccination in women of reproductive age. Serious acute respiratory syndrome coronavirus 2 is accountable for the disease COVID-19 that has annihilated the wellness and economic climate of our planet. Though vaccination versus COVID-19 began in December 2020, slower rate of immunizations has resulted in fast spread of the mutant stress of SARS-CoV-2. The SARS-CoV-2 pandemic has affected the health and wellness of humankind after the episode in Hubei, China in late December 2019. Below, we give a detailed guide on how to use low-dose high-resolution μCT to follow-up SARS-CoV-2induced illness and examination the efficacy of COVID-19 vaccine candidates in hamsters. Context The COVID-19 pandemic has resulted in a record variety of deaths in the United States and significant economic and individual pressure. Public health effects Results from these public considerations validated community assistance for strategies focusing on wellness equity, acknowledging both personal and social aspects affecting susceptability to inadequate health and wellness. Purposes To assess the desire to get a COVID-19 vaccine among Medicare recipients, the connected factors, and the factors for vaccine hesitancy. Readiness to obtain a COVID-19 vaccine was measured by participants’ solution to whether they would get a COVID-19 vaccine when readily available.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

• https://europepmc.org/article/MED/34913428 — COVID-19 booster vaccine willingness.
• https://europepmc.org/article/MED/34727554 — Scientific Evidence Supporting Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy and Safety in People Planning to Conceive or Who Are Pregnant or Lactating.
• https://europepmc.org/article/MED/34914043 — Status of COVID-19 Pandemic Before the Administration of Vaccine.
• https://europepmc.org/article/MED/34914047 — Use of Micro-Computed Tomography to Visualize and Quantify COVID-19 Vaccine Efficiency in Free-Breathing Hamsters.
• https://europepmc.org/article/MED/34797242 — Using Public Deliberation to Set Priorities: The Case of COVID-19 Vaccine Access in New York City.
• https://europepmc.org/article/MED/34081668 — Willingness to Get a COVID-19 Vaccine and Reasons for Hesitancy Among Medicare Beneficiaries: Results From a National Survey.

DOAJ — summary generated by Brevi Assistant

The arising SARS-CoV-2 variations and subsiding vaccine-elicited immunity are 2 public wellness challenges that occurred concurrently and synergistically during the summer of 2021 and brought about a surging demand for COVID-19 vaccine booster dosage rollout. This study aimed to evaluate the COVID-19 vaccine booster hesitancy among Czech health care workers to discover the prospective determinants of VBH. Intro Studies associated with the COVID-19 vaccine hesitancy are scanty in Bangladesh, in spite of the expanding need for recognizing the population behavior pertaining to vaccination. The policymakers need to think of taking another look at the policy of on the internet registration process to obtain the COVID-19 vaccine, as online enrollment is an essential structural obstacle for many due to the consistent digital divide in the nation. Vaccine hesitancy is one of the top 10 greatest hazards to global health and wellness. Recognizing these populations and their factors for vaccine hesitancy is essential in boosting vaccine uptake and suppressing the spread of COVID-19. Vaccine determination amongst the mass population, along with their appropriate understanding and understanding pertaining to injections and the vaccination process, might contribute extensively in the direction of acquiring their prepared for vaccination rates. The present research ventured to determine the Bangladeshi population’s knowledge, understanding, and readiness towards COVID-19 vaccination. SARS-CoV-2 antibody assays are vital in managing the COVID-19 pandemic. Mucosal resistance plays a major role in the fight versus COVID-19 directly at the site of infection access; nevertheless, vaccine abilities to generate mucosal immune responses have not been reported. Western countries that were first to carry out the COVID-19 vaccination report cases of vaccine-induced axillary lymphadenitis with high FDG uptake. This case of a solid immune reaction to COVID-19 vaccination in regional lymph nodes is the first reported in a Japanese patient.

Please keep in mind that the text is machine-generated by the Brevi Technologies’ Natural language Generation model, and we do not bear any responsibility. The text above has not been edited and/or modified in any way.

Source texts:

• https://doi.org/10.3390/vaccines9121437 — COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study.
• https://doi.org/10.1371/journal.pone.0260821 — COVID-19 vaccine hesitancy among the adult population in Bangladesh: A nationwide cross-sectional survey.
• https://doi.org/10.3390/vaccines9121445 — Factors Associated with COVID-19 Vaccine Hesitancy among Visible Minority Groups from a Global Context: A Scoping Review.
• https://doi.org/10.3390/vaccines9121449 — Knowledge, Perception, and Willingness towards Immunization among Bangladeshi Population during COVID-19 Vaccine Rolling Period.
• https://doi.org/10.3390/vaccines9121499 — Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection.
• https://doi.org/10.1080/25785826.2021.1999786 — New mimic of relapse or regional lymph node metastasis in a cancer survivor: a case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake.

Brief Info about Brevi Assistant

The Brevi assistant is a novel way to automatically summarize, assemble, and consolidate multiple text documents, research papers, articles, publications, reports, reviews, feedback, etc., into one compact abstractive form.

At Brevi Assistant, we integrated the most popular open-source databases to empower Researchers, Teachers, and Students to find relevant Contents/Abstracts and to always be up to date about their fields of interest.

Also, users can automate the topics and sources of interest to receive weekly or monthly summaries.